ReviewRegenerative biomaterials2026
Three-dimensional bioprinted organoids: advances and clinical translation.
Review in Regenerative biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Three-dimensional (3D) bioprinting enables the precise fabrication of complex tissue constructs by depositing living cells, biomaterials, and bioactive factors in a spatially controlled manner. Concurrently, organoids-self-organizing 3D cellular structures that recapitulate key aspects of organ architecture and function-have revolutionized biomedical research by providing physiologically relevant models for disease modeling, drug screening, and regenerative medicine. The convergence of 3D bioprinting and organoid technology represents a significant advancement, offering new opportunities for personalized medicine and tissue engineering. This review examines the current state of 3D bioprinted organoids, encompassing bioprinting techniques, bio-ink development, and diverse clinical applications spanning oncology (patient-derived tumor organoids for predicting therapy response in selected gastrointestinal cancers), regenerative medicine (bioprinted bone, cartilage, cardiac, and skin constructs), drug discovery (hepatotoxicity and nephrotoxicity screening platforms), and personalized therapeutics. We discuss technological advances supporting translational development, while distinguishing clinically validated patient-derived tumor organoid evidence from preclinical and proof-of-concept regenerative applications, and critically analyze the challenges that must be addressed for widespread clinical adoption. Finally, we provide perspectives on future directions, including the integration of artificial intelligence, multiorganoid systems, and regulatory pathways that will shape the next generation of 3D bioprinted organoids for clinical use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.